John A. Blake-Haskins

3.2k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

John A. Blake-Haskins is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John A. Blake-Haskins has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John A. Blake-Haskins's work include Cancer Immunotherapy and Biomarkers (12 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Lung Cancer Research Studies (5 papers). John A. Blake-Haskins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Lung Cancer Research Studies (5 papers). John A. Blake-Haskins collaborates with scholars based in United States, United Kingdom and Canada. John A. Blake-Haskins's co-authors include Marlon C. Rebelatto, Xiaoping Jin, Neil H. Segal, Omid Hamid, Michael S. Gordon, Ashok Gupta, John F. Kurland, Zev A. Wainberg, Winston Tan and Peter H. O’Donnell and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

John A. Blake-Haskins

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

2016 661 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by John A. Blake-Haskins

Since Specialization

Citations

This map shows the geographic impact of John A. Blake-Haskins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Blake-Haskins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Blake-Haskins more than expected).

Fields of papers citing papers by John A. Blake-Haskins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Blake-Haskins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Blake-Haskins. The network helps show where John A. Blake-Haskins may publish in the future.

Co-authorship network of co-authors of John A. Blake-Haskins

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Blake-Haskins. A scholar is included among the top collaborators of John A. Blake-Haskins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Blake-Haskins. John A. Blake-Haskins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition 2023 ·Urologic Oncology Seminars and Original Investigations ·Jens Bedke, Peter C. Black, Bernadett Szabados, Félix Guerrero‐Ramos, Shahrokh F. Shariat, Évanguelos Xylinas, Julia Brinkmann, John A. Blake-Haskins, Rossano Cesari, Joan Palou Redorta	9
2	PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL 2022 ·The Journal of Urology ·Petros Grivas, Joaquim Bellmunt, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Cora N. Sternberg, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, John A. Blake-Haskins, Robert J Laliberte, (unknown), Nuno Marques da Costa, Thomas Powles	1
3	704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 2020 ·Annals of Oncology ·Petros Grivas, S.H. Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Shilpa Gupta, Bo Huang, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Thomas Powles	10
4	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma 2016 ·Diagnostic Pathology ·Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, (unknown), Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker	135
5	Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason J. Luke, Tyler J. Curiel, Gerardo Colón‐Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal	661
6	Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer. 2016 ·Journal of Clinical Oncology ·Scott Antonia, Sang‐We Kim, Alexander I. Spira, Myung‐Ju Ahn, Sai‐Hong Ignatius Ou, Neda Stjepanovic, (unknown), Dirk Jäger, Patrick A. Ott, Zev A. Wainberg, Heather A. Wakelee, Jonathan W. Goldman, John F. Kurland, Marlon C. Rebelatto, Wenliang Yao, Ashok Gupta, John A. Blake-Haskins, Neil H. Segal	42
7	Abstract B005: An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients 2016 ·Cancer Immunology Research ·Marlon C. Rebelatto, Amita Mistry, Constantine Sabalos, (unknown), Jill Walker, Anita Midha, Keith E. Steele, Paul B. Robbins, Xia Li, Li Shi, John A. Blake-Haskins, Ramy Ibrahim, Laura K. Richman	2
8	Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. 2016 ·Journal of Clinical Oncology ·Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason J. Luke, Tyler J. Curiel, Gerardo Colón‐Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal	11
9	Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients. 2016 ·Journal of Clinical Oncology ·Brandon W. Higgs, Chris Morehouse, Katie Streicher, Marlon C. Rebelatto, Keith E. Steele, Xiaoping Jin, Fernanda Pilataxi, Philip Z. Brohawn, John A. Blake-Haskins, Ashok Gupta, Koustubh Ranade	19
10	Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. 2015 ·Journal of Clinical Oncology ·Marlon C. Rebelatto, Amita Mistry, (unknown), Jill Walker, Anita Midha, Keith E. Steele, Paul B. Robbins, Xia Li, Li Shi, John A. Blake-Haskins, Ramy Ibrahim, Laura K. Richman	25
11	Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. 2015 ·Journal of Clinical Oncology ·Xuyang Song, Min Gyoung Pak, Carlos Chávez, Meina Liang, Hong Lu, Martin Schwickart, John A. Blake-Haskins, Paul B. Robbins, Xiaoping Jin, Ashok Gupta, Lorin Roskos, Rajesh Narwal	8
12	Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. 2015 ·Journal of Clinical Oncology ·Neil H. Segal, Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, Matthew G. Fury, Erminia Massarelli, Julie R. Brahmer, Jared Weiss, Patrick Schöffski, Scott Antonia, Christophe Massard, Dan P. Zandberg, Samir N. Khleif, Xia Li, Marlon C. Rebelatto, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Marcus O. Butler	62
13	Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). 2015 ·Journal of Clinical Oncology ·Lillian L. Siu, Kyriakos P. Papadopoulos, Frank Tsai, Aaron R. Hansen, Paul B. Robbins, Xia Li, Dominic W. Lai, John A. Blake-Haskins, Matthew G. Fury	2
14	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). 2015 ·Journal of Clinical Oncology ·Naiyer A. Rizvi, Julie R. Brahmer, Sai‐Hong Ignatius Ou, Neil H. Segal, Samir N. Khleif, Wen‐Jen Hwu, Martin Gutierrez, Patrick Schöffski, Omid Hamid, Jared Weiss, Jose Lutzky, Michele Maio, John Nemunaitis, Dirk Jaeger, Ani Sarkis Balmanoukian, Marlon C. Rebelatto, Keith E. Steele, Xia Li, John A. Blake-Haskins, Scott Antonia	134
15	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. 2015 ·Journal of Clinical Oncology ·Antoni Ribas, Marcus O. Butler, Jose Lutzky, Donald P. Lawrence, Caroline Robert, Wilson H. Miller, Gerald P. Linette, Paolo A. Ascierto, Timothy M. Kuzel, Alain P. Algazi, Michael A. Postow, Paul Nathan, Brendan D. Curti, Paul B. Robbins, (unknown), John A. Blake-Haskins, Michael S. Gordon	118
16	15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients 2015 ·European Journal of Cancer ·Brandon W. Higgs, Paul B. Robbins, John A. Blake-Haskins, (unknown), Chris Morehouse, (unknown), Marlon C. Rebelatto, Yu Yao, (unknown), Libing Shi, K. Ranade	29
17	Thrombotic Microangiopathy with Targeted Cancer Agents 2011 ·Clinical Cancer Research ·John A. Blake-Haskins, Robert J. Lechleider, Robert J. Kreitman	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact